Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study.

The complement 5a receptor has been an attractive therapeutic target for many autoimmune and inflammatory disorders. However, development of a selective and potent C5aR antagonist has been challenging. Here we describe the characterization of CCX168 (avacopan), an orally administered selective and p...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Pirow Bekker, Daniel Dairaghi, Lisa Seitz, Manmohan Leleti, Yu Wang, Linda Ertl, Trageen Baumgart, Sarah Shugarts, Lisa Lohr, Ton Dang, Shichang Miao, Yibin Zeng, Pingchen Fan, Penglie Zhang, Daniel Johnson, Jay Powers, Juan Jaen, Israel Charo, Thomas J Schall
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Public Library of Science (PLoS) 2016-01-01
coleção:	PLoS ONE
Acesso em linha:	http://europepmc.org/articles/PMC5074546?pdf=render
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!